Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients.

Trial Profile

Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Genital warts; Human papillomavirus infections; Penile cancer; Vulvovaginal cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Feb 2011 Actual Initiation Date (1 May 2010) added as reported by ClinicalTrials.gov.
    • 09 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 14 May 2010 Planned initiation date changed from 1 Apr 2010 to 1 May 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top